PY30.F Galderma Group AG

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
40.00 EUR
Close of Nov 12, 2026
28.93 42.80
Market cap
EUR 46.6B
P/E
65.6x
P/B
6.24x
ROE
7.5%
Dividend yield
0.19%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is PY30.F undervalued?

Graham number

The Graham number of Galderma Group AG cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Galderma Group AG fundamental analysis

No fundamental analysis for Galderma Group AG yet.

Galderma Group AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac…

Full company profile